AstraZeneca plc (AZN) Receives Consensus Recommendation of “Hold” from Analysts

AstraZeneca plc (LON:AZN) has received a consensus recommendation of “Hold” from the twenty-one brokerages that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is GBX 5,937.73 ($77.59).

Several equities analysts have commented on AZN shares. Barclays reissued an “overweight” rating and issued a GBX 6,600 ($86.24) price target (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research report on Friday, August 10th. Cfra set a GBX 6,200 ($81.01) price target on shares of AstraZeneca and gave the company a “neutral” rating in a research report on Friday, November 9th. Credit Suisse Group reissued an “outperform” rating on shares of AstraZeneca in a research report on Monday, October 29th. Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a research report on Friday, August 31st. Finally, JPMorgan Chase & Co. set a GBX 6,900 ($90.16) price target on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, November 16th.

Shares of AZN stock opened at GBX 6,165 ($80.56) on Monday. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Liquidity

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit